FDA lifts clinical hold on phase I/II combination study of axalimogene filolisbac plus durvalumab July 16, 2018
ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine qualifies for phase II/III testing July 16, 2018
RSS